The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback